Rebecca Lenderman
Family · Sikeston, MONPI 1841658523
Payments from drug & device makers
Across 135 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$593
- Amgen$327
- Novartis$223
- Pfizer$199
- Novo Nordisk$124
- Boston Scientific$92
- plus $554 from 15 others
What the payments were for
- Food & beverage$2,111100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 46 | $593 |
| Amgen | 13 | $327 |
| Novartis | 13 | $223 |
| Pfizer | 13 | $199 |
| Novo Nordisk | 9 | $124 |
| Boston Scientific | 1 | $92 |
| Biowound Solutions, Inc. | 3 | $79 |
| Electromed, Inc. | 11 | $72 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| GSK | 5 | $70 |
| Boehringer Ingelheim | 3 | $45 |
| Eisai Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| AstraZeneca | 2 | $26 |
| Amarin Pharma, Inc. | 2 | $24 |
| Johnson & Johnson | 1 | $21 |
| Abbott | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Sanofi | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$121
How this compares
$2,111 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $43,083 |
| MounjaroTirzepatide | 20 | $21,256 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $18,214 |
| LinzessLinaclotide | 21 | $18,019 |
| GlyxambiEmpagliflozin/Linagliptin | 15 | $10,075 |
| Omeprazole | 122 | $1,502 |
| Gabapentin | 94 | $1,421 |
| Ondansetron OdtOndansetron | 13 | $1,153 |
| Baclofen | 22 | $1,038 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,024 |
| Ezetimibe | 21 | $967 |
| Potassium Chloride | 52 | $880 |
| Famotidine | 26 | $792 |
| Fluticasone Propionate | 45 | $638 |
| Diclofenac Sodium | 23 | $615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $124 | $43,08329 claims |
| AstraZenecaBreztri Aerosphere | $26 | $18,21423 claims |
| AbbVieLinzess | $593 | $18,01921 claims |
| Boehringer IngelheimGlyxambi | $45 | $10,07515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,812 family providers in Missouri.
Other family in Sikeston
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.